Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Inlexisertib |
Trade Name | |
Synonyms | DCC 3116|DCC3116|DCC-3116 |
Drug Descriptions |
Inlexisertib selectively inhibits ULK1/2, leading to decreased phosphorylation of its substrate ATG13 and inhibition of autophagosome formation, and may lead to inhibition of tumor cell growth (Mol Cancer Ther 2019;18(12 Suppl):Abstract nr B129). |
DrugClasses | |
CAS Registry Number | 2543673-19-2 |
NCIT ID | C180331 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Afatinib + Inlexisertib | Afatinib Inlexisertib | 0 | 0 |
Binimetinib + Inlexisertib | Binimetinib Inlexisertib | 0 | 1 |
Cetuximab + Encorafenib + Inlexisertib | Cetuximab Encorafenib Inlexisertib | 0 | 0 |
Inlexisertib | Inlexisertib | 0 | 1 |
Inlexisertib + Osimertinib | Inlexisertib Osimertinib | 0 | 0 |
Inlexisertib + Ripretinib | Inlexisertib Ripretinib | 0 | 1 |
Inlexisertib + Sotorasib | Inlexisertib Sotorasib | 0 | 1 |
Inlexisertib + Trametinib | Inlexisertib Trametinib | 0 | 1 |